Genetic Signatures Ltd. (AU:GSS)
ASX:GSS
Want to see AU:GSS full AI Analyst Report?
GSS Stock Chart & Stats
AU$0.24
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.24
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.60
Previous CloseN/A
Volume34.30K
Average Volume (3M)149.45K
Market Cap
AU$17.49M
Enterprise ValueAU$1.63M
Total Cash (Recent Filing)AU$29.87M
Total Debt (Recent Filing)AU$653.00K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding227,138,820
10 Day Avg. Volume161,537
30 Day Avg. Volume149,454
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.65
Price to Sales (P/S)5.20
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.10Price Target Upside-58.33% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$18.20M
Bulls Say, Bears Say
Bulls Say
Proprietary Assay TechnologyGenetic Signatures' proprietary 3base multiplex real-time PCR platform is a durable competitive asset. Multiplex capability lets labs test many pathogens from one sample, creating product differentiation, higher assay stickiness, and technical barriers that support long-term commercial adoption and R&D leverage.
Recurring Consumables Revenue ModelThe company's revenue model is anchored in recurring consumable kit sales tied to installed laboratory usage. An increasing installed base produces predictable reorder streams, smoothing revenue over time and aligning incentives for expanding assay menus that drive long-term consumable demand.
Low Leverage / Strong Equity PositionGenetic Signatures' very low debt-to-equity ratio provides durable financial flexibility. Minimal leverage reduces bankruptcy risk and preserves capacity to fund R&D and commercial expansion through equity or cash flows, an important structural advantage while the company works toward profitability.
Bears Say
Persistent Losses And Negative Cash FlowSustained net losses and negative operating and free cash flows materially weaken long-term viability unless reversed. Continued cash burn compels external funding, dilutes equity or limits investment in sales, manufacturing scale and regulatory approvals, constraining durable growth prospects.
Weak And Negative MarginsPersistent negative gross, EBIT and net margins indicate structural pricing, cost or scale issues. Without consistent margin improvement, converting revenue growth into sustainable profits is unlikely, reducing ability to self-fund expansion and eroding long-term return potential for shareholders.
Reliance On Distribution PartnersSignificant dependence on third-party distributors and commercial partners limits control over market execution, pricing and margin capture. Partner performance variability can slow adoption, create uneven revenue realization across regions, and impede building direct, durable customer relationships.
Genetic Signatures Ltd. News
GSS FAQ
What was Genetic Signatures Ltd.’s price range in the past 12 months?
Genetic Signatures Ltd. lowest share price was AU$0.07 and its highest was AU$0.59 in the past 12 months.
What is Genetic Signatures Ltd.’s market cap?
Genetic Signatures Ltd.’s market cap is AU$17.49M.
When is Genetic Signatures Ltd.’s upcoming earnings report date?
Genetic Signatures Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 97 days.
How were Genetic Signatures Ltd.’s earnings last quarter?
Genetic Signatures Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.028.
Is Genetic Signatures Ltd. overvalued?
According to Wall Street analysts Genetic Signatures Ltd.’s price is currently Overvalued.
Does Genetic Signatures Ltd. pay dividends?
Genetic Signatures Ltd. does not currently pay dividends.
What is Genetic Signatures Ltd.’s EPS estimate?
Genetic Signatures Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genetic Signatures Ltd. have?
Genetic Signatures Ltd. has 227,138,820 shares outstanding.
What happened to Genetic Signatures Ltd.’s price movement after its last earnings report?
Genetic Signatures Ltd. reported an EPS of -AU$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of Genetic Signatures Ltd.?
Currently, no hedge funds are holding shares in AU:GSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genetic Signatures Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$0.10 (-58.33% Downside)
AU$0.10 (-58.33% Downside)
Blogger Sentiment
Bullish
AU:GSS Sentiment 75%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.35%
12-Months-Change
Fundamentals
Return on Equity
-23.93%
Trailing 12-Months
Asset Growth
-16.90%
Trailing 12-Months
Company Description
Genetic Signatures Ltd.
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
GSS Stock 12 Month Forecast
Average Price Target
AU$0.10
▼(-58.33% Downside)
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
Inoviq Ltd
―